Trial reportJournal of the American Society of Nephrology : JASN2012
Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.
Trial report in Journal of the American Society of Nephrology : JASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Kidney international · 2020Guideline
- Biocompatible dialysis fluids for peritoneal dialysis.The Cochrane database of systematic reviews · 2018Pooled it
- Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis.Clinical journal of the American Society of Nephrology : CJASN · 2015Pooled it
- Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisPooled it
- BioImpedance Spectroscopy to maintain Renal Output: the BISTRO randomised controlled trial.Health technology assessment (Winchester, England) · 2025Trial
- Trial
- Trial
- Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients.BMC nephrology · 2014Trial
- The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2012Trial
- Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- The Trio Trial - A Randomized Controlled Clinical Trial Evaluating the Effect of a Biocompatible Peritoneal Dialysis Solution on Residual Renal Function.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- Is It Beneficial to Convert to a Neutral-pH Bicarbonate/Lactate-Buffered PD Solution in Long-Term CAPD Patients? A Single-Center Prospective Study.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ Trial.Peritoneal dialysis international : journal of the International Society for Peritoneal DialysisTrial
- Molecular and Functional Characterization of the Peritoneal Mesothelium, a Barrier for Solute Transport.Function (Oxford, England) · 2025Article
- The future of peritoneal dialysis.Clinical kidney journal · 2024Article
- Peritoneal dialysis-related infections in elderly patients.Clinical and experimental nephrology · 2024Review
- Associations of neutral pH, low-GDP peritoneal dialysis solutions with patient survival, transfer to haemodialysis and peritonitis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Article
- How peritoneal dialysis transforms the peritoneum and vasculature in children with chronic kidney disease-what can we learn for future treatment?Molecular and cellular pediatrics · 2022Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical benefits of using "biocompatible" neutral pH solutions containing low levels of glucose degradation products for peritoneal dialysis compared with standard solutions are uncertain. In this multicenter, open-label, parallel-group, randomized controlled trial, we randomly assigned 185 incident adult peritoneal dialysis patients with residual renal function to use either biocompatible or conventional solution for 2 years. The primary outcome measure was slope of renal function decline. Secondary outcome measures comprised time to anuria, fluid volume status, peritonitis-free survival, technique survival, patient survival, and adverse events. We did not detect a statistically significant difference in the rate of decline of renal function between the two groups as measured by the slopes of GFR: -0.22 and -0.28 ml/min per 1.73 m(2) per month (P=0.17) in the first year in the biocompatible and conventional groups, respectively, and, -0.09 and -0.10 ml/min per 1.73 m(2) per month (P=0.9) in the second year. The biocompatible group exhibited significantly longer times to anuria (P=0.009) and to the first peritonitis episode (P=0.01). This group also had fewer patients develop peritonitis (30% versus 49%) and had lower rates of peritonitis (0.30 versus 0.49 episodes per year, P=0.01). In conclusion, this trial does not support a role for biocompatible fluid in slowing the rate of GFR decline, but it does suggest that biocompatible fluid may delay the onset of anuria and reduce the incidence of peritonitis compared with conventional fluid in peritoneal dialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.